← Back to Clinical Trials
Recruiting NCT05822193

NCT05822193 Incidence, Associated Factors, and Burden of Post COVID-19 Condition in Brazil

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05822193
Status Recruiting
Phase
Sponsor Inova Medical
Condition Post-Acute COVID-19 Syndrome
Study Type OBSERVATIONAL
Enrollment 1,694 participants
Start Date 2023-07-21
Primary Completion 2025-07-01

Trial Parameters

Condition Post-Acute COVID-19 Syndrome
Sponsor Inova Medical
Study Type OBSERVATIONAL
Phase N/A
Enrollment 1,694
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-07-21
Completion 2025-07-01
Interventions
Multiple exposures

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

This is a national retrospective cohort study with internet-based recruitment which intends to enroll 1,694 adult patients with COVID-19 diagnosis during the SARS-CoV-2 omicron wave in Brazil. Participants with confirmed symptomatic COVID-19 after january 2022 will be evaluated in order to assess incidence, potential risk factors and impact of post COVID-19 condition according to the WHO definition on health-related quality of life and other relevant patient-centered outcomes.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 18 years; * Brazilian resident; * Symptomatica COVID-19 confirmed by reverse transcriptase polymerase chain reaction (RT-PCR) or antigen test for SARS-COV-2 after January 2022, with diagnosis at least 90 days before recruitment. Exclusion Criteria: * No availability to participate in remote research appointments; * Communication difficulty (aphasia, important hearing loss, non-portuguese speaker, severe dementia) * Refuse to provide informed consent

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology